Stockscreener 앱 받기
7.99
4.31%
-0.36
전일 마감가:
$8.35
열려 있는:
$8.35
하루 거래량:
1.09M
Relative Volume:
1.31
시가총액:
$404.48M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-1.519
EPS:
-5.26
순현금흐름:
$-194.72M
1주 성능:
-22.65%
1개월 성능:
-46.91%
6개월 성능:
-10.53%
1년 성능:
+9.15%
1일 변동 폭
$7.94
$8.63
1주일 범위
$7.94
$10.62
52주 변동 폭
$5.035
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.99 | 422.70M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-07 | 재개 | Raymond James | Outperform |
| 2024-11-15 | 재개 | Morgan Stanley | Overweight |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-06-07 | 개시 | Goldman | Buy |
| 2024-03-11 | 개시 | H.C. Wainwright | Buy |
| 2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 재개 | Raymond James | Outperform |
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
REGENXBIO Faces Class Action Lawsuit - Intellectia AI
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of REGENXBIO Inc. Securities and Sets a Lead Plaintiff Deadline of April 14, 2026 - GlobeNewswire Inc.
Weekly Buzz:FDA Okays NVCR's Cancer Device; RGNX Gets CRL;ONCO To Buy XBOT; PHIO's PH-762 Sets Pace - RTTNews
Rx Rundown: Eli Lilly, Supreme Group, Regenxbio and more - Medical Marketing and Media
REGENXBIO: Cautiously Bullish After FDA Setbacks (NASDAQ:RGNX) - Seeking Alpha
Can REGENXBIO Inc. be recession proofSell Signal & Consistent Profit Trading Strategies - mfd.ru
Why did RGNX shares plummet 19% after-hours today? - MSN
Regenxbio stock drops on FDA setback for RGX-121 gene therapy - MSN
2026-02-12 | REGENXBIO Inc. (RGNX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:RGNX | Press Release - Stockhouse
What is HC Wainwright's Estimate for REGENXBIO Q3 Earnings? - MarketBeat
Regenxbio highlights 56 percent women workforce on International Day of Women and Girls in Science - Traders Union
US FDA’s Rare Pediatric Disease Flexibility Rhetoric Undermined By Regenxbio’s CRL - Citeline News & Insights
Regenxbio stock price target lowered to $32 at H.C. Wainwright after FDA rejection - Investing.com Nigeria
Regenxbio (RGNX) Analyst Rating Update: Price Target Lowered by HC Wainwright | RGNX Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages REGENXBIO Inc. (RGNX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
FDA rejects RegenxBio's gene therapy for rare disease, a major setback for Rockville company - The Business Journals
FDA Delivers Regenxbio Another Blow, This Time for RGX-121 - Citeline News & Insights
Gap Down: What’s the beta of REGENXBIO Inc. stock2025 Key Lessons & Expert-Curated Trade Recommendations - baoquankhu1.vn
Goldman Sachs Lowers Price Target for RGNX, Keeps Neutral Rating - GuruFocus
FDA rejects Regenxbio treatment in another blow to gene therapy - BioPharma Dive
REGENXBIO (NASDAQ:RGNX) Price Target Lowered to $18.00 at Morgan Stanley - MarketBeat
Morgan Stanley Lowers Price Target for RGNX to $18 | RGNX Stock News - GuruFocus
Chardan Capital Lowers Price Target for (RGNX) but Maintains 'Bu - GuruFocus
The Analyst Verdict: Regenxbio In The Eyes Of 5 Experts - Benzinga
Why Is REGENXBIO Stock Falling Today?Regenxbio (NASDAQ:RGNX) - Benzinga
Chardan Capital Lowers REGENXBIO (NASDAQ:RGNX) Price Target to $50.00 - MarketBeat
Regenxbio stock price target lowered by Goldman Sachs on RGX-121 setback - Investing.com
Regenxbio Shares Fall After FDA Declines Approval of Hunter Syndrome Treatment - marketscreener.com
Regenxbio Stock Pre-Market (-18%): FDA Rejects Key Drug RGX-121 - Trefis
REGENXBIO Faces FDA Setback on RGX-121 Gene Therapy - TipRanks
Regenxbio (RGNX) Shares Dip 15% Following FDA Setback - GuruFocus
Dismay as FDA blocks Regenxbio's Hunter syndrome therapy - pharmaphorum
FDA Denies Regenxbio Gene Therapy in Latest Rare Disease Setback - Bloomberg.com
Regenxbio stock drops on FDA setback for RGX-121 gene therapy (RGNX:NASDAQ) - Seeking Alpha
Regenxbio drops after FDA rejects gene therapy for rare disease - TradingView
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
US FDA declines to approve Regenxbio’s gene therapy for rare disease - 93.3 The Drive
Regenxbio's RGX-121 Faces FDA Approval Setback - Intellectia AI
Regenxbio Stock Still Has Over 300% Upside Despite FDA Pushback On Hunter Syndrome Drug: Clear Street - Stocktwits
Why Did RGNX Shares Plummet 19% After-Hours Today? - Asianet Newsable
Bronstein, Gewirtz & Grossman, LLC Encourages REGENXBIO Inc. (RGNX) Investors to Inquire about Securities Investigation - ACCESS Newswire
FDA Slams REGENXBIO's MPS II Gene Therapy RGX-121 With CRL - CGTLive®
US FDA declines to approve Regenxbio’s rare disease drug - KFGO
Regenxbio's MPS II Gene Therapy RGX-121 Hit With CRL - NeurologyLive
Regenxbio's Gene Therapy for Hunter Syndrome Fails to Win FDA Approval - marketscreener.com
Regenxbio (RGNX) Shares Drop 21% Following FDA Setback - GuruFocus
Regenxbio falls after FDA rejects rare disease therapy - TradingView
Regenxbio (RGNX) Faces FDA Setback for Hunter Syndrome Treatment - GuruFocus
REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II - TradingView
After-hours movers: ON Semiconductor, Credo, Upwork, Regenxbio, and more - Investing.com
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Regenxbio Inc 주식 (RGNX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Simpson Curran | Chief Executive Officer |
Oct 09 '25 |
Sale |
12.62 |
20,811 |
262,635 |
216,162 |
1.12%
0.87%
자본화:
|
볼륨(24시간):